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Abstract
While it is clear that schizophrenia is highly heritable, the genetic basis of this heritability is complex. Human genetic, brain
imaging, and model organism studies have met with only modest gains. A complementary research tactic is to evaluate the
genetic substrates of quantitative endophenotypes with demonstrated deficits in schizophrenia patients. We used an
Illumina custom 1,536-SNP array to interrogate 94 functionally relevant candidate genes for schizophrenia and evaluate
association with both the qualitative diagnosis of schizophrenia and quantitative endophenotypes for schizophrenia.
Subjects included 219 schizophrenia patients and normal comparison subjects of European ancestry and 76 schizophrenia
patients and normal comparison subjects of African ancestry, all ascertained by the UCSD Schizophrenia Research Program.
Six neurophysiological and neurocognitive endophenotype test paradigms were assessed: prepulse inhibition (PPI), P50
suppression, the antisaccade oculomotor task, the Letter-Number Span Test, the California Verbal Learning Test-II, and the
Wisconsin Card Sorting Test-64 Card Version. These endophenotype test paradigms yielded six primary endophenotypes
with prior evidence of heritability and demonstrated schizophrenia-related impairments, as well as eight secondary
measures investigated as candidate endophenotypes. Schizophrenia patients showed significant deficits on ten of the
endophenotypic measures, replicating prior studies and facilitating genetic analyses of these phenotypes. A total of 38
genes were found to be associated with at least one endophenotypic measure or schizophrenia with an empirical p-
value,0.01. Many of these genes have been shown to interact on a molecular level, and eleven genes displayed evidence
for pleiotropy, revealing associations with three or more endophenotypic measures. Among these genes were ERBB4 and
NRG1, providing further support for a role of these genes in schizophrenia susceptibility. The observation of extensive
pleiotropy for some genes and singular associations for others in our data may suggest both converging and independent
genetic (and neural) pathways mediating schizophrenia risk and pathogenesis.
Citation: Greenwood TA, Light GA, Swerdlow NR, Radant AD, Braff DL (2012) Association Analysis of 94 Candidate Genes and Schizophrenia-Related
Endophenotypes. PLoS ONE 7(1): e29630. doi:10.1371/journal.pone.0029630
Editor: Kenji Hashimoto, Chiba University Center for Forensic Mental Health, Japan
Received August 31, 2011; Accepted December 1, 2011; Published January 13, 2012
Copyright:  2012 Greenwood et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by grants from the National Institute of Mental Health (NIMH; www.nimh.nih.org) to the University of California San Diego
Schizophrenia Research Project (R01-MH042228 and MH079777) and the Consortium on the Genetics of Schizophrenia (MH065571). Additional funding was
provided by a Distinguished Investigators Award from the Brain & Behavior Research Foundation (www.narsad.org) to Dr. Braff and a career development award
from the NIMH to Dr. Greenwood (K01-MH087889). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts: Dr. Greenwood has received unrelated compensation for
consulting services from INFOTECH Soft. Dr. Swerdlow received unrelated compensation for consulting services from Neurocrine. Drs. Light, Radant, and Braff
report no financial relationships with commercial interests over the past two years. This does not alter the authors’ adherence to all the PLoS ONE policies on
sharing data and materials.
* E-mail: dbraff@ucsd.edu
. These authors contributed equally to this work.
Introduction
Genetic factors clearly play a substantial role in the etiology of
schizophrenia, as evidenced by twin and other family studies that
indicate a heritability of up to 80% for this disorder [1]. Despite
replicated linkage evidence implicating chromosomes 1q, 5q, 6p,
6q, 8p, 10p, 13q, 15q, and 22q [2] and the identification of several
putative susceptibility genes [3,4], a causative gene or variant for
schizophrenia has yet to be definitively identified. One strategy
that may aid in identifying the genetic substrates of a complex
disorder, like schizophrenia, is to interrogate specific candidate
genes thought to be associated with the underlying neurobiology of
the disorder or with its associated endophenotypes [5]. To this
end, we have constructed a custom SNP array containing 1,536
SNPs in 94 genes that were chosen based on hypotheses regarding
biological systems of relevance to schizophrenia, as well as an
extensive review of published linkage, association, gene expression,
brain imaging, and model organism studies [6]. This custom SNP
array provides excellent coverage of many previously suggested
and functionally important candidate genes for schizophrenia,
including AKT1, CHRNA7, COMT, DAO, DAOA, DISC1,
DTNBP1, ERBB4, GRM3, GSK3B, NOS1AP, NRG1, PA-
FAH1B1, PPP3CC, PRODH, RELN, and RGS4 [3,4]. Many of
the genes represented on the array have also been reported to be
involved in brain development and heritable endophenotypes
associated with schizophrenia. A similar approach has been used
in recent studies of addictive disorders [7] and eating disorders
[8,9].
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candidate gene analysis via this custom SNP array to evaluate the
association of six neurophysiological and neurocognitive endo-
phenotypes related to schizophrenia, including prepulse inhibition
(PPI) of startle, P50 suppression, the antisaccade task, the
California Verbal Learning Task-II (CVLT-II), the Letter-
Number Sequencing test (LNS), and the Wisconsin Card Sorting
Test-64 Card Version (WCST-64). These endophenotypes were
chosen based on demonstrated deficits in schizophrenia patients
and prior evidence of reliability, stability, and heritability of the
derived measures [5,10–13]. Impaired performance on these
endophenotypes has also been demonstrated in clinically unaf-
fected relatives of schizophrenia patients, which provides further
evidence that these deficits may reflect part of the heritable risk for
the illness [14–29]. The endophenotype test paradigms also
yielded eight secondary measures, which were evaluated as
candidate endophenotypes. We investigate the utility of endophe-
notypes in facilitating the dissection of the genetic architecture and
heritability of schizophrenia [5,6].
Methods
Subject Ascertainment
Subjects were recruited locally through the UCSD Schizophre-
nia Research Program and included males and females between
the ages of 18–65. Schizophrenia outpatients (SZ) were recruited
from community board and care facilities and were carefully
screened to rule out drug abuse or dependence within the past 6
months and neurologic insults. Diagnoses were confirmed using
the Structured Clinical Interview for DSM-IV Axis I Disorders
(SCID) [30]. Normal comparison subjects (NCS) answered
advertisements and underwent comprehensive clinical interviews
via the SCID-Non Patient Edition [31] and SCID-II [32] to rule
out other Axis I or II diagnoses (cluster B) and a toxicological
screen was performed to rule out current drug abuse. After a
detailed description of study participation, written informed
consent was obtained for each subject in accordance with
protocols 040564 and 071831 as approved by the University of
California San Diego Human Research Protections Program.
The case-control sampling strategy provides for a broad range
of phenotypic variation in the genetic analyses of these quantitative
endophenotypes, since the object of the study was to explore the
genetic architecture of quantitative neurophysiological and
neurocognitive endophenotypes underlying schizophrenia suscep-
tibility, not necessarily the genetic basis of schizophrenia itself.
Additionally, subjects both unaffected and affected with schizo-
phrenia are needed in order to understand how a particular
endophenotype contributes to schizophrenia. The current sample
includes 322 subjects (203 SZ and 119 NCS). The composition of
the sample is approximately 68% subjects of European ancestry,
23% subjects of African ancestry, 4% subjects of Asian ancestry,
and 5% of more than one race according to self-reported ethnicity.
Note that this sample is completely independent of the previously
published Consortium on the Genetics of Schizophrenia (COGS)
family-based study [6,12].
Phenotypes
Six endophenotype test paradigms were chosen based on their
demonstrated deficits in schizophrenia patients and prior evidence
of reliability, stability, and heritability of the derived measures
[5,10–13]. These endophenotype test paradigms yielded a variety
of quantitative measures, including six primary endophenotypes
and eight secondary, candidate endophenotypic measures that
ranged from largely automatic, neurophysiological measures to
highly volitional, neurocognitive measures, as described below
[33].
Three neurophysiological endophenotypic test paradigms were
assessed. Prepulse inhibition (PPI) of startle was defined as the
percent inhibition of the startle reflex caused by a weak prestimulus
presented 60 msec prior to a startling stimulus [34–36]. We also
assessedtwosecondarymeasuresrelated tostartle:startlemagnitude
on non-prepulse trials (reactivity) and percent startle habituation
from the first to final block of testing. The primary endophenotype
of P50 suppression was the ratio of the amplitudes of the P50 event-
related potentials generated in response to the conditioning (S1) and
test (S2) stimuli presented with a 500 msec interstimulus interval
[37]. Secondary measures also considered were the S1–S2
difference, S1 amplitude, and S2 amplitude. The ‘‘overlap’’
antisaccade test of oculomotor inhibition, which assesses the
prefrontal-mediated capacity to inhibit a prepotent response,
requires subjects to fixate on a central target and respond to a
peripheral cue by looking in the opposite direction at the same
distance. The primary endophenotype of antisaccade performance
was quantified by determining the ratio of correct antisaccades
divided by the total number interpretable saccades [38,39].
Three neurocognitive endophenotypic test paradigms were also
assessed. The Letter-Number Span (LNS) is a prototypical task to
assess working memory information storage with manipulation. A
primary endophenotype was measured as the correct reordering of
intermixed numbers and letters (working memory, LNS re-order),
and a simple repetition of these letters and numbers in the order
dictated was considered a secondary measure (immediate recall,
LNS forward) [29,40]. To assess verbal learning and memory, we
used the California Verbal Learning Test, Second Edition (CVLT-
II). The primary endophenotype for this test was the total recall
score of a list of 16 verbally presented items immediately after
presentation summed over 5 trials (immediate recall), and a
secondary measure of recall after a 20-minute delay was also
considered (delayed recall) [41]. The Wisconsin Card Sorting
Test-64 Card Version (WCST-64) [13] was used to assess execu-
tive function according to our established procedures [42]. The
number of perseverative responses was considered the primary
endophenotype with the categories completed as the secondary
measure.
Custom 1,536-SNP Array
We used a candidate gene approach in an attempt to identify
genes contributing to the expression of the primary endopheno-
types and secondary phenotypic measures. A custom SNP array
including 1,536 SNPs within 94 candidate genes was created, as
described elsewhere in detail [6], and utilized here. These genes
were selected based on complementary information from linkage,
association, gene expression, brain imaging, and model organism
studies of schizophrenia, as well as knowledge of biological systems
particularly relevant to schizophrenia. The resulting array
included all of the commonly cited candidate genes for
schizophrenia (e.g., COMT, DISC1, DTNBP1, and NRG1), as
well as genes from pathways of likely relevance to schizophrenia.
Haplotype-tagging SNPs were obtained from the TAMAL website
and selected from the HapMap CEU population [43] to efficiently
interrogate these genes in our sample of primarily European
ancestry. We included 5 kb of flanking sequence on either side of
each gene to capture nearby regulatory regions in our tagged
regions. Additional SNPs were also included based on prior
evidence of association with schizophrenia. The custom array
included 1,417 haplotype tagging SNPs for 86 genes, 116 SNPs in
33 genes with reported evidence of association, 29 coding
sequence variants in 17 genes (25 nonsynonymous and 4
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or transcription factor binding sites. On average, there was 1 SNP
per 10 kb for each gene with variance due to linkage disequilib-
rium patterns and SNP availability. Minor allele frequencies for
these SNPs ranged from 0.01 to 0.50, with an average of 0.23. The
complete list of all 1,536 SNPs and 94 candidate genes included on
the array and the specific details from our research is available in
Table S1 (see References S1 for included references) and
elsewhere [6], including rs numbers, chromosomal locations, gene
information, designation of SNPs (e.g., as tagging, coding,
putatively functional, or associated, including p-values and
references), relevant sequence information, and minor allele
frequencies for the four HapMap populations. Ingenuity Pathway
Analysis (IPA, IngenuityH Systems) was used to generate a genetic
network detailing the interactions between 42 of the 94 genes on
the SNP chip, as well as to provide information regarding the
clustering of the 94 genes into functional pathways.
DNA Extraction
Whole blood was drawn from all subjects and placed in
anticoagulant (EDTA) tubes for storage at 280uC. The ACCUS-
PIN System-HISTOPAQUE-1077 (Sigma-Aldrich) was used for
the isolation of lymphocytes from the whole blood, and DNA was
extracted using PUREGENE DNA Purification Reagents (Gen-
tra). The genomic DNA was quantified using the Quant-iT
PicoGreen dsDNA reagent, and purity was assessed by measuring
the UV absorbance.
Genotyping and Cleaning
A total of 203 SZ and 119 NCS were genotyped using 20 mlo f
genomic DNA at 50 ng/ml plated on 96-well plates with three
positive controls per plate, and genotyping was performed by the
Biomedical Genomics Laboratory (BIOGEM) at UCSD using an
Illumina BeadStation 500 Scanner. Genotype data were cleaned
using Illumina’s BeadStudio v.3 software for allele calling. Each
subject was evaluated across all 1,536 SNPs, and all subjects were
found to have acceptable allele call rates, defined as an average call
rate .80% and a 50% GenCall Score (median genotype call
score) .0.76. Each SNP was then evaluated across all subjects,
and 38 SNPs were excluded for having average call rates ,90%
and cluster separation scores ,0.05. Another 95 SNPs were
eliminated following a manual examination of all SNPs with call
rates .90% but cluster separation scores between 0.05 and 0.25.
A total of 133 SNPs were thus removed due to poor allele call rates
and/or cluster separation, resulting in a 91.4% SNP assay
conversion rate. The final group of 1,403 passing SNPs had a
genotype call rate of 99.98%, and accuracy estimated from
replicate DNA samples genotyped across the panel indicated a
99.98% reproducibility rate. Further quality control assessments
using the PLINK analysis toolset [44] identified two SNPs with
Hardy-Weinberg Equilibrium p-values,10
24 in the controls and
28 SNPs with minor allele frequencies ,0.01 in this sample.
Removal of these additional SNPs resulted in 1,373 SNPs for
association analysis, the minor allele frequencies of which
approximated those observed in the HapMap CEU population.
The effective number of independent SNPs for analysis was
determined to be 977, after accounting for redundancies in linkage
disequilibrium due to the inclusion of putatively functional and/or
associated SNPs along with tagging SNPs and gene-spanning
SNPs [45].
Statistical Analyses
Only the ten primary and secondary endophenotypic measures
revealing significant (p,0.05) mean differences between the SZ
and NCS groups of European ancestry were considered in the
association analyses (see Table 1). SZ and NCS groups were
combined for these analyses to increase the range of phenotypic
variation in each measure. One expects that the phenotypic
distributions will overlap between these groups, as some control
subjects will show deficits and some SZ subjects will not show
deficits for any given measure due to the incomplete correlations of
these measures with schizophrenia diagnosis. We have found this
to be the case in our sample, and these measures were
approximately normally distributed after the removal of outlying
values defined as more than three standard deviations from the
mean. There were three such outlying values observed for P50 S1
amplitude, one for PPI, and five for startle habituation.
Multidimensional scaling (MDS), implemented in PLINK [44],
was used to assess the degree of population stratification in this
sample and to validate the self-reported subject ethnicities, which
are not always reliable. Based on a comparison of the MDS
results and the self-reported ethnicities, the largest and most
genetically homogenous group included subjects of European
ancestry, which formed 68% of the sample and encompassed 219
subjects (127 SZ and 92 NCS). This group of subjects was
selected for the primary analyses of the phenotypic measures. We
anticipate .80% power to detect a locus explaining 5% of the
trait variation at a p-value,0.01 and 10% of the variation at a p-
value,1610
24 in this sample. A secondary sample of 76 subjects
of African ancestry (62 SZ and 14 NCS) was chosen for follow-up
analyses of the most salient findings in the subjects of European
ancestry. Subjects of Asian ancestry were very few in number.
Those who reported ancestry of more than one race that did not
cluster with either the subjects of European or African ancestry in
the MDS analysis were also few in number and genetically
heterogeneous. These 28 total subjects were thus eliminated from
further analysis.
Association analyses between the SNPs and the ten primary and
secondary endophenotypic measures were conducted using linear
regression methods in PLINK [44], whereas logistic regression
methods were employed for the analysis of schizophrenia
diagnosis. Age and sex were explored as covariates for all
endophenotypes via correlation analyses and incorporated into
the association analyses when significant as follows: both age and
sex for P50 S1 amplitude, the antisaccade task, LNS re-order,
CVLT-II immediate and delayed recall, and WCST-64 persev-
erative responses; and sex only for WCST-64 categories complete.
The first two MDS principal components were also used as
covariates in all association analyses of the European and African
ancestry subjects separately to correct for any residual population
stratification within the two groups.
We did not consider years of education or scores from the Wide
Range Achievement Test (WRAT) as potential covariates in these
analyses. While education is an important correlate of neurocog-
nitive abilities that may confound genetic association findings, the
handling of potential covariates with substantive group differences,
such as that demonstrated by education, is not trivial. Schizo-
phrenia patients typically display lower-than-normal levels of
education and significantly reduced performances across all
neurocognitive measures, as is demonstrated in this sample. Since
schizophrenia is a neurodevelopmental disorder characterized by
heritable cognitive deficits that are detectable prior to the onset of
illness, it is not possible to disentangle the confounding multivariate
inter-relationships of schizophrenia status, cognitive abilities, years
of formal education, and genetic risk. The use of factors as
covariates that are directly impacted by, and may in fact be intrinsic
to, schizophrenia would effectively control for case status in this
case-control study.
Genetic Associations of Schizophrenia Phenotypes
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ate empirical significance levels. Permutations also provide for a
more accurate assessment of the association of lower frequency
alleles (e.g., minor allele frequencies of 0.01–0.10) with a modest
sample size. For each SNP and phenotypic measure, permutations
were performed in an adaptive fashion such that the number of
permutations performed for a given SNP was relative to the original
significance value, with more permutations performed for smaller
(more significant) p-values. All association p-values presented are
empirical and the result of these adaptive permutations. While all
SNPs with minor allele frequencies .0.01 were included in the
association analyses, we only present the results for the more
commonSNPswithfrequencies .0.05.Thecompleteresultscanbe
found in Table S1, including the SNPs with frequencies ,0.05.
Results
Prior to conducting association analyses, we performed some
initial assessments of the primary endophenotypes and secondary
endophenotypic measures to validate their informativity in the 219
subjects of European ancestry. Table 1 lists the mean values for all
quantitative phenotypic measures in the SZ and NCS groups, as
well as the significance of the mean differences. All neurocognitive
measures from the LNS (forward and re-order), CVLT-II
(immediate and delayed recall), and WCST-64 (perseverative
responses and categories completed) revealed robust and highly
significant differences (d=0.60 to d=1.71, p,0.001) between the
SZ and NCS groups. Of the neurophysiological measures, the
antisaccade task and PPI revealed highly significant differences
(d=1.14 and d=0.51, respectively, p,0.001), whereas startle
habituation and P50 S1 amplitude revealed more modest but still
significant differences (d=0.36, p,0.05). The remaining neuro-
physiological measures (i.e., startle magnitude, P50 suppression
and difference score, and P50 S2 amplitude) revealed only small
differences (d,0.28) between the SZ and NCS groups and were
thus excluded from further analyses.
We also assessed the degree of correlation between the
endophenotypic measures in the subjects of European ancestry,
as shown in Table 2. Age and sex were also assessed as potential
covariates, and both were at least moderately associated with most
measures (see Table 2). The correlational analyses among
endophenotypic measures revealed a pattern of robust (p,0.001)
inter-correlations among the majority of neurocognitive measures
and the antisaccade task. Other neurophysiological measures,
however, revealed fewer and more modest correlations with the
neurocognitive measures. No significant correlations were ob-
served among the neurophysiological measures.
Analysis of the ten endophenotypic measures that significantly
differentiated the SZ and NCS groups revealed associations with
34 of the 94 genes collectively, with the qualitative schizophrenia
diagnosis revealing associations to four additional genes. Figure 1
provides a summary of the minimum empirical p-values for each
gene and endophenotype, and the complete set of results is
presented in Table S1. Among these 38 genes, there were four
SNPs with empirical p-values,10
24, 14 SNPs with empirical p-
values,10
23, and 98 SNPs with empirical p-values,0.01. The
most significant finding in these analyses was for a SNP in
CTNNA2 with the LNS re-order measure, which gave an
empirical p-value of 3.1610
25. Three other SNPs gave empirical
p-values,10
24 as follows: NRG1 for P50 S1 (p=7.2610
25),
COMT for startle habituation (p=8.2610
25), and CACNG2 for
CVLT-2 delayed recall (p=5.3610
25). We also found evidence to
support association to two nonsynonymous SNPs: NRG1
Arg38Gln gave an empirical p=6.2610
23 for WCST-64
perseverative responses, and GRIN2B His1399His gave an
empirical p=6.6610
23 for CVLT-II immediate recall.
Table 1. Descriptive statistics for the primary and secondary endophenotypic measures in the SZ and NCS subjects of European
ancestry.
SZ NCS Effect
N Mean (SD) N Mean (SD) Size (d)
Age* 126 45.33 (9.02) 92 42.46 (11.11) 20.29
WRAT-3 Reading Standard Score** 125 94.87 (14.20) 91 107.69 (9.08) 1.06
Prepulse Inhibition (PPI)** 90 42.48 (27.22) 72 55.74 (24.01) 0.51
Startle Magnitude 116 64.24 (56.81) 89 73.39 (50.49) 0.17
Startle Habituation (Hab)* 82 48.45 (33.17) 71 59.00 (28.24) 0.34
P50 Suppression 91 52.37 (31.97) 79 56.66 (27.29) 0.14
P50 S1–S2 Difference 90 1.50 (1.13) 78 1.85 (1.41) 0.28
P50 S1 Amplitude (P50-S1)* 89 2.75 (1.34) 79 3.33 (1.94) 0.36
P50 S2 Amplitude 89 1.23 (0.90) 80 1.42 (1.05) 0.2
Antisaccade** 107 0.53 (0.26) 89 0.80 (0.21) 1.14
LNS Immediate Recall (LNS-fwd)** 125 12.28 (3.20) 92 14.18 (3.06) 0.60
LNS Working Memory (LNS-reorder)** 125 7.82 (2.75) 92 11.33 (2.58) 1.31
CVLT-II Immediate Recall (CVLT-immed)** 125 35.88 (11.01) 92 53.75 (9.75) 1.71
CVLT-II Delayed Recall (CVLT-delay)** 125 7.64 (3.38) 92 11.96 (2.96) 1.35
WCST-64 Perseverative Responses (WCST-persev)** 123 21.33 (16.77) 92 11.00 (9.18) 20.76
WCST-64 Categories Completed (WCST-cat)** 124 2.03 (1.57) 92 3.43 (1.52) 0.90
Phenotypes with significant differences between the schizophrenia patient (SZ) and normal comparison subject (NCS) groups are indicated in bold.
*p,0.05;
**p,0.001.
doi:10.1371/journal.pone.0029630.t001
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shown prior allelic or haplotypic associations with schizophrenia or
related phenotypes [6]. In our analyses, we found further evidence
for association to CACNG2, CHRNA7, COMT, DISC1, DRD3,
ERBB4, GABRB2, GRID1, GRIK3, GRIK4, GRIN2B, HTR2A,
NCAM1, NEUROG1, NOTCH4, NRG1, PRODH, SLC1A2,
and SLC6A3, as detailed in Figure 1, including associations to ten
specific SNPs with previous reports of association to schizophrenia
[46–53]. In contrast to our expectations, we did not find evidence
for association to ADRBK2, AKT1, BDNF, DAO, DAOA,
Table 2. Correlations between the significantly different endophenotypic measures in the SZ and NCS subjects of European
ancestry.
Age Sex PPI Hab
P50-
S1
Anti-
saccade
LNS-
fwd
LNS-
reorder
CVLT-
immed
CVLT-
delay
WCST-
persev
PPI ns ns
Hab ns ns ns
P50-S1 20.20* 0.17* ns ns
Antisaccade 20.19* 0.14* ns ns ns
LNS-fwd ns ns 0.18* ns 0.20* 0.23*
LNS-reorder 20.16* 0.24* 0.29** ns ns 0.46** 0.56**
CVLT-immed 20.25** 0.31* 0.23* 0.19* 0.18* 0.51** 0.36** 0.70**
CVLT-delay 20.23* 0.26* 0.18* 0.18* ns 0.37** 0.28** 0.60** 0.86**
WCST-persev 0.20* 20.14* ns ns ns 20.34** 20.21* 20.40** 20.43** 20.34**
WCST-cat ns 0.16* ns ns ns 0.43** 0.26** 0.47** 0.53** 0.45** 20.75**
Key: ns=not significant;
*p,0.05;
**p,0.001.
doi:10.1371/journal.pone.0029630.t002
Figure 1. Summary of the most significant associations observed in the European ancestry sample. Empirical p-values are presented for
each of the 38 genes with each of the 10 phenotypes and schizophrenia using a minimum empirical p-value of ,0.01 as a threshold. Note that not all
associations to the same gene across phenotypes reflect associations to the same SNP, although many do. An asterisk (*) indicates that at least one
SNP in the gene associated with the specified phenotype has been previously associated with schizophrenia as follows: rs963468 in DRD3 [46],
rs2344485 in NEUROG1 [47]; rs520692 in NOTCH4 [48,49]; rs1954787 in GRIK4 [50]; rs1805247 in GRIN2B [51,52]; and rs2267341 and rs2283981 in
CACNG2 [53]. Genes associated with three or more phenotypes are indicated in bold.
doi:10.1371/journal.pone.0029630.g001
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GRM4, HTR7, PPP1R1B, PPP3CC, RGS4, SLC18A1, SP4,
TAAR6, or ZDHHC8, despite previous reports.
Figure 1 also highlights the associations of genes across the
endophenotypic measures. Eleven genes displayed extensive
evidence for pleiotropy, revealing associations with three or more
phenotypes and often with schizophrenia as well. These genes
included GRIK3, NOS1AP, CTNNA2, ERBB4, GRID2, RELN,
NRG1, GRIK4, GRIN2B, CHRNA7, and CACNG2. In contrast,
other genes were found to be associated with a single endopheno-
typicmeasureand/orschizophreniaonly.Theseresults maysuggest
the involvement of multiple pathways in mediating schizophrenia
susceptibility.
As expected, the 94 candidate genes on the chip cluster into
multiple pathways thought to be of relevance to schizophrenia,
which is a highly heterogeneous disorder. These included cell
signal transduction, axonal guidance, amino acid metabolism, and
dopamine, GABA, glutamate, and serotonin receptor signaling.
The 38 genes significantly associated with at least one endophe-
notypic measure or schizophrenia itself are distributed amongst
these pathways, as shown in Figure 2. There is a notable cluster of
associated genes in the glutamate signaling pathway where 9 of the
16 genes revealed associations to at least one phenotype, and five
genes (GRID2, GRIK3, GRIK4, GRIN2A, and GRIN2B) were
associated with more than one endophenotypic measure. We also
explored the underlying molecular interactions between a subset of
the 94 genes on the custom SNP chip using Ingenuity Pathway
Analysis, as shown in Figure 3. Networks detailing the interactions
between genes found to be associated with at least one
neurophysiological or neurocognitive measure are highlighted
separately and reveal overlapping yet distinct patterns of gene
involvement between the neurophysiological and neurocognitive
phenotypic domains.
We attempted to replicate and extend these findings in the
subjects of African ancestry collected as part of this sample. We
included for analysis only those 11 genes that revealed extensive
evidence for pleiotropy in the European ancestry sample as
discussed above. As shown in Figure 4, we found further evidence
to support association to all but GRIK4 (see Table S1 for a
complete description of the results). Several of the genes (GRIK3,
NOS1AP, CTNNA2, ERBB4, GRID2, RELN, NRG1) revealed a
similar pattern of associations across the endophenotypic measures
to that observed in the European ancestry sample. While most of
the genes were associated with more than one endophenotypic
measure, four genes (ERBB4, GRID2, RELN, and NRG1) once
again displayed extensive pleiotropy with associations to four or
more endophenotypic measures.
Discussion
In this study, we assessed six neurophysiological and neurocog-
nitive primary endophenotypes with prior evidence of heritability
and demonstrated schizophrenia-related impairments, as well as
eight secondary endophenotypic measures derived from the
endophenotype test paradigms. Ten of the endophenotypic
measures successfully differentiated between schizophrenia pa-
tients and controls. Analysis of these endophenotypic measures
revealed an expected pattern of robust correlations (p,0.001)
among the neurocognitive phenotypes, consistent with many
studies demonstrating a generalized and inter-dependent pattern
of neurocognitive deficits in schizophrenia (e.g. [54–60]). The
antisaccade task was also significantly correlated with the
neurocognitive phenotypes, whereas other neurophysiological
measures revealed expectedly fewer and more moderate correla-
tions with the neurocognitive measures [33,37,61]. However, no
significant correlations were observed among the neurophysiolog-
ical endophenotypes, suggesting that these measures represent
independent neurobiological processes with distinct neural and
genetic substrates.
Association analyses of the ten endophenotypic measures
differing between schizophrenia patients and controls identified
both singular genetic associations, as well as genes exhibiting
pleiotropic effects across several endophenotypic domains. Specif-
ically, we observed associations between the ten endophenotypic
measures and 36 genes thought to be of biological relevance to
Figure 2. Distribution of the 94 candidate genes in known biological pathways. Associated (empirical p,0.01) genes are indicated in bold,
and those associated with more than one phenotype are additionally indicated with an asterisk (*).
doi:10.1371/journal.pone.0029630.g002
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chosen based on neurobiological relevance and prior association
with schizophrenia, those revealing associations with multiple
endophenotypic measures may be of particular interest. Indeed,
ERBB4, GRID2, RELN, and NRG1 in particular revealed
extensive pleiotropy across the endophenotypic measures in both
the European and African ancestry samples, offering a compell-
ing picture of the global importance of these genes in the
Figure 3. Genetic network detailing the types of interactions between a subset of the 94 candidate genes. Genes associated (empirical
p,0.01) with at least one neurophysiological phenotype (PPI, startle habituation, and P50 S1) are highlighted in yellow in (A), and genes associated
(empirical p,0.01) with the neurocognitive phenotypes (antisaccade, LNS forward, LNS re-order, CVLT-II immediate recall, CVLT-II delayed recall,
WCST-64 perseverative responses, or WCST-64 categories) are highlighted in (B). Note that antisaccade was grouped with the neurocognitive
phenotypes based on its demonstrated correlations with these measures (see Table 2). Genes are represented as nodes, and the biological
relationship between two nodes is represented as an edge (line or arrow) supported by at least one reference from the literature, a textbook, or
canonical information derived from the human, mouse, and rat orthologs of the gene that are stored in the Ingenuity Pathways Knowledge Base.
Solid and dashed lines/arrows indicate direct and indirect interactions, respectively.
doi:10.1371/journal.pone.0029630.g003
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deficits. We also observed a notable cluster of associated genes
in the glutamate signaling pathway, which is consistent with other
reports that have shown genes in cellular signaling and
neurodevelopmental processes, including the neuregulin and
glutamate pathways, to be disproportionately disrupted in
schizophrenia [6,62]. Overall, the observation of extensive
pleiotropy for some genes and singular associations for others in
our data may suggest the presence of both overlapping and distinct
pathways mediating schizophrenia pathogenesis.
This pattern of results is similar to that seen in the recently
published analyses of an independent family-based sample from
the Consortium on the Genetics of Schizophrenia (COGS) [6].
While both the COGS study and that presented here have utilized
the same 1,536 custom SNP array for the assessment of genetic
associations with neurophysiological and neurocognitive endophe-
notypes for schizophrenia, the particular endophenotypes assessed,
the ascertainment schemes employed, and the computational
methods used for analysis are quite distinct between the two
studies. The COGS ascertained families through probands with
schizophrenia who had at least one unaffected sibling and both
parents available for testing and used variance component
methods to evaluate genetic associations of the quantitative
endophenotypes in their family-based sample. For the current
study, we recruited all available schizophrenia patients regardless
of family availability, along with healthy controls, and used linear
regression methods to evaluate genetic associations of the
quantitative endophenotypes in our sample of unrelated subjects.
The COGS study also used a novel bootstrap method to correct
for multiple comparisons, since simple permutation schemes, such
as that used here, cannot accommodate family-based samples with
quantitative traits and covariates. The combination of the
aforementioned differences makes a point-by-point comparison
of the results of these two studies difficult. Nevertheless, if we
compare the overall results of the current study with those from
the COGS study, we find that nine genes feature very prominently
in both samples: GRIK3, NOS1AP, CTNNA2, ERBB4, GRID2,
RELN, NRG1, GRIK4, and GRIN2B. We also find a total of 28
genes that are associated with at least one endophenotype in both
samples, many of which cluster in the glutamate pathway.
Collectively, these results support a strong role for genes involved
in glutamate signaling in mediating schizophrenia susceptibility
and/or endophenotype deficits.
With the analysis of 94 candidate genes and ten endophenotypic
measures, the issue of multiple comparisons must be considered.
However, correction for multiple testing is not trivial in this case,
since many of the ten endophenotypes are significantly inter-
correlated and are therefore cannot be considered independent
(see Table 2). This fact makes a correction for multiple phenotypic
comparisons challenging. Further complicating the issue, 40 of the
genes on the chip (42%) were selected based on a priori evidence
of association to schizophrenia in the literature, so the analyses of
these genes could be considered ‘‘modified replication studies.’’
Since a p-value of 0.05 is often considered an adequate threshold
for replication, applying a Bonferroni correction based on the total
number of SNPs analyzed (977) and requiring a p-value of
5610
25 for significance, is clearly not appropriate and is overly
conservative in this type of situation. We have thus utilized
permutation procedures to provide for a more accurate assessment
of association between each locus and endophenotypic measure.
We have also analyzed a subset of the genes identified in the
subjects of European ancestry in an independent, albeit small,
sample of African ancestry to replicate and extend the initial
results in a genetically distinct population.
A possible limitation of this study is the assessment of lower
frequency SNPs through linear regression in a sample of modest
size. Permutation procedures were used to provide a more
accurate assessment of the observed associations, which is
particularly critical for lower frequency SNPs. However, one
might argue that a higher minor allele threshold for inclusion
should be used. There are 85 SNPs with minor allele frequencies
of 1–5%, three of which are nonsynonymous coding variants of
potentially high interest. While we have assessed all SNPs meeting
our allele frequency threshold of 1%, we highlight only the results
for SNPs with frequencies of at least 5%, providing the complete
results in Table S1.
Studies of disorders as heterogeneous as schizophrenia are
replete with failures to replicate findings. The selected endophe-
notypes themselves also present several challenges. For example,
molecular, animal model, and human genetic studies of P50
suppression deficits in schizophrenia present an elegant and logical
picture. However, in this study, P50 suppression measured both by
ratio and difference score methods failed to reveal significant
differences between the SZ and NCS groups. In contrast,
schizophrenia patients showed a significantly diminished ‘‘S1’’
response to the first of the two-click paired stimuli. Moreover,
important methodological differences might also account for our
failure to detect significant P50 gating deficits in this sample as well
as across other laboratories [63]. Additionally, antipsychotic
medications may affect these results, although they tend to
‘‘normalize’’ endophenotypic scores (e.g. [35,64]), thereby reduc-
ing, rather than increasing, the probability of association. Genetic
analyses of schizophrenia are also plagued by nonreplication (e.g.
[65]), despite the striking heritability of the disorder [1]. Here, too,
we found no evidence for association to some prominent
schizophrenia candidate genes, such as DAO, DAOA, DTNBP1,
PPP3CC, and RGS4 [3,4]. These inconsistencies are understand-
able in the context of ascertainment biases, population stratifica-
tion, and cohort variance due to gender, smoking, treatment, age
of onset, and a plethora of other factors. The present sample size
Figure 4. Summary of the most significant associations
observed in the African ancestry sample. Empirical p-values are
presented for each of the 11 genes exhibiting pleiotropy in the analyses
of the European ancestry sample with each of the 10 phenotypes and
schizophrenia using a minimum empirical p-value of ,0.01 as a
threshold. Note that not all associations to the same gene across
phenotypes reflect associations to the same SNP, although many do.
doi:10.1371/journal.pone.0029630.g004
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gene-phenotype associations and definitively identify non-associ-
ations. Additionally, the degree of allelic, locus, and phenotypic
heterogeneity in schizophrenia patients now appears to be far
more extensive than previously appreciated, which, combined with
emerging evidence for epigenetic effects and many individual-
specific rare variants, may have important implications for gene
discovery [66,67].
Overall, these data reflect and extend our knowledge of the
genetic basis of neurophysiological and neurocognitive endophe-
notypes related to schizophrenia and of schizophrenia itself. Each
study into this research domain should be viewed as one building
block in constructing a comprehensive picture of the genetic basis
of schizophrenia. Further analyses of the genes associated with
each of these endophenotypes may provide additional information
regarding the underlying genetic pathways involved in schizo-
phrenia susceptibility and endophenotype deficits. By further
refining the observed associations with each endophenotype,
identifying the underlying causal genetic variants, and elaborating
their molecular interactions, the field will be better positioned to
understand the underlying genetics and neuropathology of this
common, polygenic disorder and hopefully to facilitate early
identification and individualized treatment strategies for schizo-
phrenia patients.
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